AstraZeneca’s Fasenra (benralizumab) hit a roadblock in attempting to expand the medicine’s indications when the U.S. Food and Drug Administration issued a Complete Response Letter for chronic rhinosinusitis with nasal polyps (CRSwNP).
Regeneron, Sanofi Blockbuster Dupixent Scores Points in 5 More Indications
Asthma, Atopic Dermatitis (Eczema), Blockbusters, Chronic Idiopathic Urticaria, Chronic rhinosinusitis with nasal polyps (CRSwNP), Clinical Trials, ENT Diseases, Eosinophilic Esophagitis, Human Antibodies, Immunosuppressants, Prurigo nodularis, R&D, Regeneron Pharmaceuticals, Rhinosinusitis, Sanofi, TherapeuticsRegeneron Pharmaceuticals and Sanofi’s anti-inflammatory drug Dupixent (dupilumab) has shown to be effective against five types of type 2 inflammations, with more indications expected to surface soon.
The U.S. Food and Drug Administration approved GlaxoSmithKline plc’s Nucala (mepolizumab), a monoclonal antibody that targets interleukin-5, as a treatment for patients with chronic rhinosinusitis with nasal polyps (CRSwNP).
Sanofi Reports Strong Second-Quarter 2019
Acquisitions, Analysts, Asthma, Atopic Dermatitis (Eczema), Business, China, Chronic Rhinosinusitis, Diabetes, Earnings per share (EPS), European Medicines Agency, FDA, Future Blockbusters, Hemophilia, Insulin, Product Launches, Profitability, Quarterly results, R&D, Relapse/Refractory Multiple Myeloma, VaccinesSanofi reported overall net sales increased by 5.5 percent for second-quarter 2019, driven by Sanofi Genzyme, Sanofi Pasteur and emerging markets.
FDA approves expanded label for Regeneron/Sanofi’s Dupixent
Analysts, Approvals, Asthma, Atopic Dermatitis (Eczema), Biologics, Blockbusters, Chronic Obstructive Pulmonary Disease (COPD), Chronic Rhinosinusitis, Corticosteroids, Environmental Allergies, Eosinophilic Esophagitis, Expanded Label, FDA, FDA/Regulatory, Food Allergies, Nasal PolypsThe U.S. Food and Drug Administration approved Regeneron Pharmaceuticals Inc. and Sanofi SA’s drug Dupixent to treat nasal polyps, marking the third major use for the injectable medicine.